Annexon to Present at the Raymond James Human Health Innovation Conference
Rhea-AI Summary
Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, will have its President & CEO, Douglas Love, present at the Raymond James Human Health Innovation Conference on June 23, 2021, at 1:20 pm EDT. The conference will focus on the company's pipeline of novel therapies targeting classical complement-mediated autoimmune and neurodegenerative disorders. Investors can access a live webcast under the 'Events & Presentations' section on the Investors page of www.annexonbio.com, with an archived replay available for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – ANNX
In the trading session that priced this news, ANNX gained 0.13%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, announced that Douglas Love, Esq., President & Chief Executive Officer, will present at the virtual Raymond James Human Health Innovation Conference on June 23rd, 2021 at 1:20 pm EDT.
A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
About Annexon, Inc.
Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is deploying a disciplined, biomarker-driven development strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.